Rheumatology Therapeutics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024

1
Rheumatology Therapeutics Market Global Industry
Analysis, Trends, Market Size and Forecasts up
to 2024
2
The latest report on Rheumatology Therapeutics
Market by Infinium Global Research gives complete
coverage of the Rheumatology Therapeutics Market
by drug class (disease modifying anti-rheumatic,
nonsteroidal anti-inflammatory, corticosteroids,
uric acid drugs), disease indication (rheumatoid
arthritis, osteoarthritis, gout, psoriatic
arthritis, ankylosing spondylitis), distribution
channel (hospital, retail, online pharmacy) in
terms of key trends, market size, forecast and
CAGR growth over the period of 2018 to 2024. In
addition, the study covers deep dive into key
product and applications trends in the regional
markets of Rheumatology Therapeutics such as
North America, Europe, Asia-Pacific and Latin
America over the short run and long run. Get a
Sample Request https//www.infiniumglobalresearch
.com/reports/sample_request/1129 The report on
global rheumatology therapeutics market is an in
depth analysis of the segments and sub- segments
in the rheumatology therapeutics market. The
report provides analysis for the global as well
as regional markets over the period of 2016 to
2024. According to report the global rheumatology
therapeutics market is expected to grow at a
CAGR of 2.52 over the forecast period of 2018 -
2024. Market Insight Ardea Biosciences received
approval from FDA for Duzallo (lesinurad and
allopurinol) which help to treatment of
hyperuricemia associated with gout. According to
FDA, Duzallo combination of two medications with
complementary mechanisms of action with contain
lesinurad, a uric acid reabsorption inhibitor,
and allopurinol, a xanthine oxidase inhibitor.
Duzallo lowers serum uric acid levels by
increasing excretion and inhibiting production
of uric acid. Duzallo is specifically indicated
for the treatment of hyperuricemia associated
with gout in patients who have not achieved
target serum uric acid levels with a medically
appropriate daily dose of allopurinol alone.
Recently, Sanofi and Regeneron announce FDA
approval of Kevzara (sarilumab) for the
treatment of moderately to severely active
rheumatoid arthritis in adult patients.
3
Kevzara is an interlukin-6 receptor antibody,
which is used for treating adult patients with
moderate to severe stages of active rheumatoid
arthritis (RA) who have shown indecisive response
or intolerance to one or more non-biologic or
biologic DMARDs i.e. Disease Modifying Anti
Rheumatic Drugs. The development of new drugs
which help to treat this diseases more
effectively called biologics, or disease
modifying agents. The increasing elderly
population worldwide and approval of new drugs
for treating various rheumatic diseases, the
growing awareness among society about the
treatment of rheumatic diseases and lucrative
environment of the treatment has driven the
growth of the market. Additionally high funding
for research and development activities is
likely to boost the growth of the
market. Segments Covered The report on global
rheumatology therapeutics market covers segments
such as drug class, disease indication, and
distribution channel. The drug class segments
include disease modifying anti-rheumatic drugs,
nonsteroidal anti-inflammatory drugs,
corticosteroids, uric acid drugs and others. On
the basis of disease indication the global
rheumatology therapeutics market is categorized
into rheumatoid arthritis, osteoarthritis, gout,
psoriatic arthritis, ankylosing spondylitis and
others. Furthermore, on the basis of
distribution channel the rheumatology
therapeutics market is segmented as hospital
pharmacy, retail pharmacy and online
pharmacy. Make an Enquiry https//www.infiniumglo
balresearch.com/reports/enquiry/1129 Geographic
Coverage The report provides regional analysis
covering geographies such as North America,
Europe, Asia-Pacific, and Rest of the World. In
this section the key trends and market size for
each geography is provided over the period of
2016 2024. The countries covered in the North
America region include the U.S., Canada, and
Mexico while Asia-Pacific includes China, Japan,
India, South Korea and Malaysia among others. The
U.S.
4
drives the growth in the North America region as
it is the largest market in the region. The
Asia-pacific region offers a substantial
potential for the market growth owing to rapid
growth in markets such as India and China. The
APAC region is projected to experience a healthy
growth in terms of CAGR over the period of 2018 -
2024. Among the regions North America estimated
to be the largest market share on accounts of
prevalence of rheumatic arthritis in the
U.S. and Canada. Growing healthcare expenditure
among the families in the emerging markets such
as China, India among others coupled with
increasing geriatric population in the region
are likely to drive the growth in the
Asia-Pacific region, as a result the Asia-Pacific
rheumatology market is projected to grow at the
swiftest CAGR over the forecast
period. Companies Profiled The report provides
profiles of the companies in the global
rheumatology therapeutics market such as, Takeda
Pharmaceutical, Sanofi, Genentech, Inc., Novartis
AG, Janssen Biotech, Inc., Amgen, Inc., AbbVie,
Inc., Pfizer, Inc., Bristol-Myers Squibb
Company, and Merck Co., Inc. Click the Below
Full Report Link https//www.infiniumglobalresear
ch.com/healthcare_medical_devices/global_rheumatol
ogy_therapeutics _market Report Highlights The
report provides deep insights on demand
forecasts, market trends and micro and macro
indicators. In addition, this report provides
insights on the factors that are driving and
restraining the Global rheumatology therapeutics
market. Moreover, IGR-Growth Matrix analysis
given in the report brings an insight on the
investment areas that existing or new market
players can consider. The report provides
insights into the market using analytical tools
such as Porters five forces analysis and DRO
analysis of rheumatology therapeutics
market. Moreover, the study highlights current
market trends and provides forecast from 2018 to
2024. We also have highlighted future trends in
the rheumatology therapeutics market that will
impact the demand during the
5
forecast period. Moreover, the competitive
analysis given in each regional market brings an
insight on the market share of the leading
players. Additionally, the analysis highlights
rise and fall in the market shares of the key
players in the market. This report will help the
key players operating in the rheumatology
therapeutics market to understand the present
and future trends in this market and formulate
their strategies accordingly.